SynthesisPloS one2022

Survival modelling and cost-effectiveness analysis of treatments for newly diagnosed metastatic hormone-sensitive prostate cancer.

Michaela C Barbier et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.